A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established.

Slides:



Advertisements
Similar presentations
Chronic Kidney Disease Manju Sood GPST3. What is CKD? Chronic renal failure is the progressive loss of nephrons resulting in permanent compromise of renal.
Advertisements

Lysaght, J Am Soc Nephrol, 2002 Number of patients worldwide treated with chronic dialysis from 1990 to ,000 1,490,000 2,500,000.
Chronic kidney disease: [insert title here] Insert name, title, date here Insert acknowledgements here.
The PREVEND Study: Screening for micro-albuminuria
General Practice Workshop This workshop was conceived and developed by Kidney Health Australia’s Kidney Check Australia Taskforce with particular thanks.
Efficacy of Sodium Bicarbonate Infusion in Reversal of Acute Renal Failure 1 NEPHRO 2014 June 25-28, 2014 Valencia, Spain.
CKD In Primary Care Dr Mohammed Javid.
Canadian Diabetes Association Clinical Practice Guidelines Chronic Kidney Disease in Diabetes Chapter 29 Phil McFarlane, Richard E. Gilbert, Lori MacCallum,
1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.
Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States Ian H. de Boer, MD, MS, Tessa C. Rue, MS, Yoshio N. Hall, MD, Patrick.
Proteinuria Outcome Lupus Nephritis Classes of Lupus Nephritis I.Minimal II.Mesangial III.Focal proliferative* IV.Diffuse proliferative* V.Membranous**
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
A retrospective cohort study of Childhood post-streptococcal glomerulonephritis as a risk factor for chronic renal disease in later life Andrew V White,
Mugendi AG, BPharm, MPharm (Clin Pharm). Comparison of the effects of losartan and enalapril on renal function in adults with chronic kidney disease at.
Association of 1,5-Anhydroglucitol with Diabetes and Microvascular
Lesley Stevens MD Tufts-New England Medical Center
Prevalance of Chronic Kidney Disease 26 million people have diagnosed chronic kidney 26 million people have diagnosed chronic kidney disease (CKD) ( National.
Change in prevalence of Chronic Kidney Disease in England over time: comparison of nationally representative cross-sectional surveys from 2003 to 2010.
Management of Chronic Kidney Disease Stages 1 – 3 Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Diabetic Nephropathy Case Presentations. UA (Urine Dipstick) Use as an initial screen for all patients Negative to trace proteinuria requires further.
Early Detection and Prevention of Renal Failure Linda Fried, MD, MPH.
Hemoglobin A 1c in Hemodialysis Patients Source: Ix JH. Hemoglobin A1c in hemodialysis patients: Should one size fit all? Clin J Am Soc Nephrol. 2010;5:1539–1541.
Section 4: Managing progression of CKD. Glomerulosclerosis Reduction in number of functioning glomeruli Increased blood flow to remaining nephrons Intraglomerular.
RENAL DISEASE IN DIABETES
Diabetic Nephropathy Yiming Lit, M.D. May 5, 2009.
6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.
New Concepts in Chronic Kidney Disease Jonathan B. Jaffery, MD Assistant Professor of Medicine University of Wisconsin-Madison.
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
Diabetic Nephropathy in the Adolescent Age Group Henry Rodriguez, M.D. Associate Professor of Pediatrics Indiana University School of Medicine Director,
Stage 4 CKD presentation in patients over 75 Years Old differs from that in patients less than 75 Years of Age Hiromichi Suzuki, Tsutomu Inoue,Tomohiro.
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study) Lambers Heerspink,
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
Mrs. Watcharasa Pitug ID The Association between Waist Circumference and Renal Insufficiency among Hypertensive Patients 15/10/58 1.
Proteinuria as a surrogate outcome in CKD UKPDS Rudy Bilous Middlesbrough, UK.
Mrs. Watcharasa Pitug ID The Association between Waist Circumference and Renal Insufficiency among Hypertensive Patients 20/10/58 1.
Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Albuminuria; a tool for measuring non-blood pressure.
Dr M Sivalingam Renal Unit, Lister Hospital, Stevenage.
Case Report and Lit Review: Reduction of Proteinuria in Diabetic Nephropathy with Spironolactone Harry W. Floyd, M.D. Family Medicine Kingstree, South.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
Chapter 1: CKD in the General Population 2015 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
Hypertension Control and Progression of Renal Disease
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Predicting Progression in Diabetic Nephropathy: New Biomarker: sTNFR1* Circulating soluble Tumor Necrosis Factor Receptor 1.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Trial profile Mann JF et al. Lancet 2008;372:
Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease S Bianchi, R Bigazzi and VM Campese Kidney.
The Evaluate Trial. Rationale and Design of the Eplerenone Combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Risk Involved with Dual RAAS Blockade in Kidney Disease Source: Bakris GL. Dual RAAS blockade is desirable in kidney disease: Con. Kidney Int. 2010;78:546–549.
The DVD Trial. Source Reinecke H, Fobker M, Wellmann J, et al. A randomized controlled trial comparing hydration therapy to additional hemodialysis or.
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
Updates in Diabetic Nephropathy Rodica Pop-Busui, M.D., Ph.D Division of Metabolism, Endocrinology and Diabetes Michigan Comprehensive Diabetes Center.
Am J Kidney Dis. 2014;63(6): R3 박세정 /prof. 이태원 Comparative Effectiveness of Early Versus Conventional Timing of Dialysis Initiation in Advanced.
The FRET Study Source: Inoue T, Ikeda H, Nakamura T, et al. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin.
Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive.
Circulation. 2014;129: Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy.
Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
Changes in the concentration of serum C-peptide in type 2 diabetes during long-term continuous subcutaneous insulin infusion therapy Department of Internal.
Chronic Kidney Disease (CKD) Dr. Sham Sunder. Now we know why the titanic sank !! < 0.5 % 5- 10%
Estimated Glomerular Filtration Rate and Albuminuria Are Associated with Biomarkers of Cardiac Injury in a Population-Based Cohort Study: The Maastricht.
Section 4: Managing progression of CKD
Effects of Uric acid- lowering therapy on renal outcomes: a systematic review and meta-analysis Nephrol Dial Transplant (2014) 29: Vaughan Washco.
From: Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney DiseaseA Secondary Analysis.
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
So What is Albuminuria? An elevated urinary albumin excretion is a marker of endothelial dysfunction that symbolizes the kidney’s way to translate the.
I. Introduction American Journal of Kidney Diseases
Nat. Rev. Cardiol. doi: /nrcardio
GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration 
Table of Contents Why Do We Treat Hypertension? Recommendation 5
American Journal of Kidney Diseases
Presentation transcript:

A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established conventional therapy for glycemic control, blood pressure control, and the use of inhibitors of the renin-angiotension- aldosterone system. Residual proteinuria is associated with progression of kidney disease, indicating the need for additional treatment. Vitamin D therapies have been used for over 50 years in chronic kidney disease (CKD) patients for treatment of renal osteodystrophy. The prevalence of low vitamin D levels is increasing globally. Epidemiological studies have shown that low vitamin D level are common in patients with albuminuria. There is emerging evidence indicating that vitamin D may have antiproteinuric and renoprotective effects in patients with CKD. Previous studies have shown that the selective vitamin D receptor activator, paricalcitol, and large dose of cholecalciferol effectively reduced proteinuria in patients with type 2 DM. Long-term study of the use of regular doses of oral supplementation of vitamin D and the effect on albuminuria and kidney function has never been studied. INTRODUCTION Baseline1 yearP value 25(OH)Vitamin D level20.78SD SD Creatinine0.91SD SD eGFR78.91SD SD Urine microalbumin23.83SD SD Hb A1C7.302SD SD LDL88.82SD SD HDL43.84SD SD Triglyceride122.61SD SD Vit D at baseline Low < 30 n = 147 Normal >30 n = 13 Vit D at 1 yr Low < 30 n = 58 Normal > 30 n = 89 Low < 30 n = 4 Normal > 30 n = 9 Group1234P value Mean ∆Vit D 4.328SD SD SD SD Mean ∆Cr SD SD 0.130SD SD Mean ∆eGFR 0.32SD SD SD SD Mean ∆U Microalb SD SD SD SD RESULTS This study aims to evaluate the effect of vitamin D on kidney function (GFR) and urine microalbumin in type 2 diabetic population. OBJECTIVE Over 2,000 type 2 diabetic patients seen in the clinic from January 2009 to December 2013 were screened. Total of 160 patients aged between 40 to 65 years old who meet inclusion criteria were included in the study. Vitamin D level, urine microalbumin, Hb A1C, LDL, HDL, and triglyceride were collected at baseline and 1 year after. All patients had been on stable dose of ACEI or ARB before study period and maintained on the same dose during 1 year study period. Data were analyzed for significant changes between baseline and at 1 year follow up. Patients were divided into 4 groups based on vitamin D levels for further analysis. Statistical analyses were performed using JMP software version Data are expressed as the mean +/- Standard deviation (SD) or mean +/- inter quartile range for continuous variables and as frequency and percentage for categorical variables. Comparisons between groups were performed using analysis of variance (ANOVA). METHOD There were increases in vitamin D level and eGFR, decreases in creatinine level, and LDL at 1 year follow up with P value < 0.01 (Table1). However, there were no statistical differences for the change in urine microalbumin, Hb A1C, HDL, and triglyceride. It is unclear that the change in LDL is related to vitamin D supplementation or other factors as some of our patients had been on statin therapy with different intensities and had dose adjusted during study period. In subgroup analysis (Table 2 and Figure 1), the decreases in creatinine and urine microalbumin, or the improvement in eGFR were not associated with the improvement in vitamin D level. Non-significant results can be possibly due to a small sample size in each sub-group. The linear regression analysis showed positive correlation between ∆vitamin D and ∆eGFR, and negative correlation between ∆vitamin D and ∆Cr, ∆urine microalbumin. However, these correlations were not statistically significant. (Figure 2) Previous studies demonstrated a potential therapeutic effect of vitamin D in decreasing albuminuria. Our results are not consistent with some previous studies. This inconsistency might be due to different types (active vs nutritional) and doses of vitamin D supplementation as well as duration of supplementation in our subjects. Further randomized controlled trial are needed to establish the correlation and long-term outcome. DISCUSSION Based on our research analysis, low vitamin D levels were common in type 2 diabetic patients, and vitamin D repletion was shown to improve renal function (GFR) without antiproteinuric effect. Vitamin D level should be routinely checked in type 2 diabetic patients as appropriate vitamin D supplementation may help slow the progression of CKD. CONCLUSION 1. de Zeeuw, D., et al., Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet, (9752): p de Boer, I.H., et al., Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. Clin J Am Soc Nephrol, (9): p Huang, Y., et al., Oral supplementation with cholecalciferol 800 IU ameliorates albuminuria in Chinese type 2 diabetic patients with nephropathy. PLoS One, (11): p. e Kim, M.J., et al., Oral cholecalciferol decreases albuminuria and urinary TGF-beta1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int, (8): p REFERENCES Table 1 Summary of follow-up resultsTable 2 Subgroup analysis Figure 1 Subgroup analysis Microalbuminuria year1-year0 Creatinine year1-year0 GFR year1-year0 Vitamin D year1-year Figure 2 Correlation analysis p = p = p = p < p = p = p =